| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d27f8ef05191b1c730fd4e1f87f20609
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_be14cf234e66dd4611736c1532d2aed2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16222
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16234
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2469-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56994
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-085
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6854
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-245 |
| filingDate |
2015-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7cc582394f8000ce3c46e0458d60b4cb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a44e59ddcdf9642f6c0fe0344326c85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71bf53b9a5b3ede4c8cd21eceb72fd60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_437c084b78c146ccba84eeb0ae1ae588
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7fc389a1dc26fd8a8b7ad5ac630bf81 |
| publicationDate |
2018-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10016494-B2 |
| titleOfInvention |
Antigenic epitopes from EBV gp350/220 and uses thereof |
| abstract |
The present invention relates to a peptide comprising (A) (i) a first domain comprising an amino acid sequence having at least 60% sequence similarity with the sequence PDDRTLQ (SEQ ID NO:1); and (ii) a second domain covalently linked to the first domain and comprising an amino acid sequence having at least 60% sequence similarity with the sequence QNPVYLIPETVPYIKWDN (SEQ ID NO:2) or (B) (i) a first domain comprising an amino acid sequence having at least 60% sequence similarity with the sequence GSAKPGNGSYF (SEQ ID NO: 41); and (ii) a second domain covalently linked to the first domain, said second domain comprising an amino acid sequence having at least 60% sequence similarity with the sequence SVKTEMLGNEID (SEQ ID NO: 42), wherein the peptide binds to monoclonal antibody clone 72A1. This peptide may be useful for inducing the production of neutralizing antibodies against a gp350-expressing herpesvirus, such as Epstein-Barr virus (EBV), for example for immunizing or vaccinating an animal against a gp350-expressing herpesvirus, as well as for detecting the presence or absence neutralizing anti-gp350-expressing herpesvirus antibodies in a sample. |
| priorityDate |
2014-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |